Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach

Keramatinia, Aliasghar; Ahadi, Alireza; Akbari, Mohammad Esmaeil; Mohseny, Maryam; Jarahi, Alireza Mosavi; Mehrvar, Narjes; Mansouri, Neda; Tabatabaei, Seyed Abdolreza Mortazavi; Movafagh, Abolfazl

doi:10.15430/jcp.2017.22.2.74

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RASSF6 expression strongly increases in some cancers (ovarian cancer). In some cases, this protein is pro-tumorigenic like Hippo suppression RASSF4 82 …”

Section: Rassf6mentioning

confidence: 99%

The Role and Function of Ras-association domain family in Cancer: A Review

et al. 2019

Self Cite

View full text Add to dashboard Cite

Ras gene mutation has been observed in more than 30% of cancers, and 90% of pancreatic, lung and colon cancers. Ras proteins (K-Ras, H-Ras, N-Ras) act as molecular switches which are activated by binding to GTP. They play a role in the cascade of cell process control (proliferation and cell division). In the inactive state, transforming GTP to GDP leads to the activation of GTpase in Ras gene. However, the mutation in Ras leads to the loss of internal GTPase activity and permanent activation of the protein. The activated Ras can promote the cell death or stop cell growth, which are facilitated by Ras-association domain family. Various studies have been conducted to determine the importance of losing RASSF proteins in Ras-induced tumors. This paper examines the role of Ras and RASSF proteins. In general, RASSF proteins can be used as a suitable means for targeting a large group of Ras-induced tumors.

show abstract

“…RASSF6 expression strongly increases in some cancers (ovarian cancer). In some cases, this protein is pro-tumorigenic like Hippo suppression RASSF4 82 …”

Section: Rassf6mentioning

confidence: 99%

The Role and Function of Ras-association domain family in Cancer: A Review

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…A kromoszómatörés egy adott génen belül különböző helyeken történhet meg, ennek fügvényében megkülönböztetünk major, minor és mikro-BCR-ABL gént, amely az átíródott onkoprotein nagyságát tekintve 210 kD (p210 Bcr/Abl ), 190 kD (p190 Bcr/Abl ), illetve ritkábban 230 kD (p230 Bcr/Abl ). Az átíródott onkoprotein fokozott tirozinkináz-aktivitással rendelkezik, ami a sejtosztódást és -differenciálódást szabályozva létrehozza a transzformációt [5]. Az imatinib (STI571), egy kis molekulájú tirozinkináz-gátló (TKI) jelentette az első célzott kezelést a konstitucionálisan aktív BCR-ABL kinázaktivitásának gátlására, és a TKI hamar a CML alapvonalbeli kezelésévé vált [6].…”

Section: Eredeti Közleményunclassified

Krónikus myeloid leukaemiás betegek követése a Marosvásárhelyi Hematológiai és Csontvelő-átültetési Klinika beteganyagában 2008 és 2018 között

Tunyogi¹,

Lázár

Benedek

et al. 2019

Orvosi Hetilap

View full text Add to dashboard Cite

Introduction and aim: Chronic myeloid leukemia is a clonal myeloproliferative disorder characterized by the BCR-ABL gene rearrangement with translocation between chromosomes 9 and 22. The constitutively active BCR-ABL tyrosine kinase inhibitor became the standard frontline therapy. The molecular monitoring is essential. Method: We studied the chronic myeloid leukemia patients at the Clinical Hematology and Bone Marrow Transplant Unit Tg-Mures between 2008 and 2018. Results: We followed 59 patients, median age of 45 years, female : male ratio 1.5 : 1. 80% of the patients were in chronic phase. Sokal score was low in 61%, intermediate 27% and high in 12% of the patients. The median follow-up time was 5 years and 9 months. 59% of the patients reached molecular remission (average time 11 months). The cumulative overall survival was 80% at 5 years and 76% at 10 years. The overall survival according to disease phase was 98%, 85%, 20%; according to Sokal score it was 91%, 66%, 51%. The cumulative progression-free survival was 75% at 5 years and 50% at 10 years. Only 8% of the low risk patients are progressing opposite to 77% of the high risk patients. The cumulative probability to maintain the molecular remission for 5 years is 100%, for 10 years 91% and for 15 years 52%. Conclusion: A rising level of BCR-ABL is an early indication of the loss of response identifying the patients who need close monitoring and therapeutic change. Orv Hetil. 2019; 160(2): 67–72.

show abstract

Paraneoplastic Syndromes

Bailey¹

2019

Withrow and MacEwen's Small Animal Clinical Oncology

View full text Add to dashboard Cite

Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach

Cited by 4 publications

References 39 publications

The Role and Function of Ras-association domain family in Cancer: A Review

The Role and Function of Ras-association domain family in Cancer: A Review

Krónikus myeloid leukaemiás betegek követése a Marosvásárhelyi Hematológiai és Csontvelő-átültetési Klinika beteganyagában 2008 és 2018 között

Paraneoplastic Syndromes

Contact Info

Product

Resources

About